About this trial
In this study, researchers examined the changes in related indicators such as immune function, splenic vein,proper hepatic artery, and portal venous hemodynamics following laparoscopic resection of a splenic artery aneurysm. We determined the changes in these patient-related indicators after surgical treatment and whether these changes could improve patient outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Asymptomatic splenic artery aneurysms with a diameter>2 cm,ruptured splenic artery aneurysms,and splenic artery aneurysms with a diameter increase>0.5 cm/year.
Disqualifiers
Patients with malignancies Hepatic cirrhosis with portal hypertension peptic ulcer disease Recent peptic ulcer disease History of Hemorrhagic stroke Pregnancy hematological diseases Uncontrolled Hypertension Human immunodeficiency virus (HIV) infection
Trial design
Single group
Treatments tested in this trial
laparoscopic resection of splenic artery aneurysm with preservation of spleen
Procedure/SurgeryThe laparoscopic resection of splenic artery aneurysm with preservation of spleen is performed by the same surgical team.
Treatment groups
Trial outcomes
Primary outcomes
The immune function at 7 days after surgery
The level of the immune function(Complement C3; Complement C4; IgG; IgA; IgM;CD19;CD20;CD16;CD56;CD3;CD4) at 7 days after surgery.
The immune function at 1 month after surgery
The level of the immune function(Complement C3; Complement C4; IgG; IgA; IgM;CD19;CD20;CD16;CD56;CD3;CD4) at 1 month after surgery.
The immune function at 3 months after surgery
The level of the immune function(Complement C3; Complement C4; IgG; IgA; IgM;CD19;CD20;CD16;CD56;CD3;CD4) at 3 months after surgery.
The immune function at 6 months after surgery
The level of the immune function(Complement C3; Complement C4; IgG; IgA; IgM;CD19;CD20;CD16;CD56;CD3;CD4) at 6 months after surgery.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.